Tabuk Pharma has entered into a strategic partnership with Althera Laboratories to introduce an innovative treatment for type 2 diabetes across the MENA region. This collaboration reinforces Tabuk Pharma’s commitment to expanding value-added therapeutic solutions and enhancing healthcare quality, in alignment…
Tabuk Pharma Signs Strategic Agreements with Local Content and Government Procurement Authority at Global Health Exhibition 2025
As part of the Global Health Exhibition 2025, Tabuk Pharma signed two strategic agreements with the Local Content and Government Procurement Authority, marking a significant milestone in strengthening pharmaceutical localization and advancing the Kingdom’s healthcare capabilities. These agreements reflect a shared…
Tabuk Pharma Signs Exclusive License and Supply Agreement with Hanmi Pharmaceutical for Rolontis® (Eflapegrastim) in Saudi Arabia and MENA
Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis® (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Arabia and the MENA region. This strategic collaboration underscores Tabuk Pharma’s commitment to expanding…
Tabuk Pharmaceuticals Announces Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20, an innovative First in class arginine degradation platform for hard-to-treat cancers in the Kingdom of Saudi Arabia and GCC Region.
Strategic Collaboration to Address Critical Healthcare Needs and Expand Access to Life-Changing Treatments Riyadh – Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceutical company, today announced an exclusive licensing agreement with Polaris, a…
Tabuk Pharmaceuticals Expands Strategic Partnership with HK inno.N to Include Additional MENA Markets for K-CAB® (Tegoprazan)
Riyadh, Saudi Arabia – [May 7 2025] — Tabuk Pharmaceuticals, a leading Saudi pharmaceutical company with a strong regional footprint across the Middle East and North Africa (MENA), announced today the expansion of its strategic collaboration with HK inno.N for the…
Tabuk Pharmaceuticals Announces Exclusive Licensing Partnership with Hanmi to Introduce Innovative Value-Added Medicines in the Kingdom of Saudi Arabia and MENA Region
Riyadh – Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceutical company, today announced an exclusive licensing partnership with Hanmi, a renowned South Korean pharmaceutical company, to introduce novel value-added medicines to the Middle…
Biocon Limited partners with Tabuk Pharmaceuticals to commercialise its Glucagon-like peptide-1 (GLP -1) products in the Middle East region.
Tabuk Pharmaceuticals Partners with Biocon to Bring GLP-1 Diabetes and Weight Management Therapies to the Middle East Riyadh – Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group and one of the leading pharmaceutical companies in the Middle…
Formosa Pharmaceuticals Announces Exclusive Licensing Agreement with Tabuk Pharmaceuticals, for the Commercialization of Clobetasol Propionate Ophthalmic Suspension, a Novel Medicine for the Treatment of Inflammation and Pain Following Ocular Surgery
Riyadh – Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, announced today an exclusive license agreementwith Formosa Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine…
Tabuk Pharmaceuticals and Globalpharma Sign an Agreement to Locally manufacture Key Pharmaceutical products in UAE.
Globalpharma and Tabuk Pharmaceuticals, leaders in the pharmaceutical industry in the Middle East and North Africa, announced the signing of a cooperation agreement aimed at enabling local manufacturing of several products by Tabuk Pharmaceuticals in the United Arab Emirates. The signing…
Tabuk Pharmaceuticals Partners with Bio-Thera Solutions forRights to Manufacture and Commercialize BAT2206,a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia
Manufacturing Company (a fully-owned subsidiary of Astra Industrial Group), a leading pharmaceutical company in the Middle East and North Africa (MENA) region, today announced the signing of a license, manufacturing, supply and commercialization agreement with Bio-Thera Solutions Inc. (688177:SH), a commercial-stage…